Function of a lens protein betaA3/A1-crystallin in astrocytes
星形胶质细胞中晶状体蛋白 betaA3/A1-晶状体蛋白的功能
基本信息
- 批准号:10366476
- 负责人:
- 金额:$ 39.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2024-09-29
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAnimal ModelApoptosisArteriesAstrocytesAutophagocytosisBlindnessBlood VesselsCell DeathCharacteristicsChildChildhoodClinicalCombined Modality TherapyComplexCrystallinsDataDeletion MutationDevelopmentDiseaseEndothelial CellsEnsureEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorEtiologyEyeEye DevelopmentFRAP1 geneFailureGefitinibGoalsIndiaInheritedInjectionsKnockout MiceLeadLinkLysosomesMinorityModalityMonitorMusOperative Surgical ProceduresOrphanOutcomePatientsPharmaceutical PreparationsPhenotypePostoperative HemorrhagePrevalenceProcessProtein IsoformsProteinsPublishingRare DiseasesResolutionRetinaRetinal DegenerationScanningSeveritiesSeverity of illnessSiteSpecimenSupporting CellTestingTherapeuticTissuesTractionTransgenic MiceUnited StatesVEGFA geneVascular Endothelial Growth FactorsVisionVisualVitrectomybasecohortdiabeticdietaryfetalfunctional lossgene therapyin vivo Modelknock-downlensmigrationmouse modelmutantnovel therapeutic interventionoverexpressionpromoterreconstructionrelease factorretina blood vessel structuretherapeutic targettherapeutically effectivetranscription factor
项目摘要
Project Summary:
The fetal, or hyaloid, vasculature nourishes the lens and retina during ocular development, subsequently
regressing after the formation of retinal vessels. The failure of the fetal vasculature to regress leads to serious
problems with vision, a condition known as persistent fetal vasculature (PFV) disease. The exact prevalence of
PFV is unknown; however, a study on childhood blindness and visual loss in the United States showed that
PFV accounts for 5% of all childhood cases of blindness. A major finding from our previous studies on PFV is
that astrocytes abnormally migrate into the vitreous and ensheath the hyaloid artery, suggesting a direct cause
and effect relationship between astrocyte association and vascular retention. Astrocytes are not known to be
involved in either the formation or regression of the hyaloid artery. Our data suggested that the defective
lysosomal function in astrocytes is linked to increased astrocyte migration and ensheathment of the hyaloid
artery. Several mouse models of PFV, in addition to those we have studied, appear to have astrocytes
associated with the persistent hyaloid artery. Importantly, we have also shown that astrocytes abnormally
ensheath the hyaloid artery in clinical specimens from PFV patients. PFV involves persistence of components
of the normally transient fetal intraocular vasculature and can vary widely in terms of completeness and
severity. While increased vascular endothelial growth factor (VEGF) in the vitreous is certainly an important
factor in the etiology of severe PFV, it is likely not the case in mild or moderate PFV. Our focus in this proposal
is to develop a therapy for mild/moderate disease. PFV is a complex and heterogeneous disease and no single
therapy is likely to be effective for all patients. Appropriate treatment may well depend upon disease severity.
With severe disease with a fibrotic stalk, the drug(s) that we develop here may be efficacious if given prior to
vitrectomy, analogous to anti-VEGFA injections being given prior to vitrectomy for diabetic traction detachment
to make the surgery technically simpler with reduced intraoperative and postoperative hemorrhaging. Here we
will test the hypothesis that “restoring normal astrocyte function is an effective therapeutic strategy for
PFV disease”. This objective will be accomplished by pursuing the following Specific Aims: Specific Aim 1:
To demonstrate if A1-crystallin overexpression can rejuvenate astrocyte function and thereby rescue the
PFV-like phenotype; Specific Aim 2: To test if inhibiting gefitinib and activating autophagic lysosomal
reformation triggers normal regression of the hyaloid vasculature and Specific Aim 3: To identify factors
released by A1 KD astrocytes that could inhibit normal developmental remodeling (regression) of the fetal
vasculature. The proposed study is significant because we now have the appropriate animal models to test
novel therapeutic approaches to treat PFV based on our studies. It is apparent that most children with PFV
have a poor visual outcome. Therefore, even if only a minority of patients significantly benefit from the
treatment, it would still be an important therapeutic advance.
项目概要:
胎儿或玻璃体脉管系统在眼发育期间覆盖透镜和视网膜,随后
在视网膜血管形成后退化。胎儿脉管系统的退化失败导致严重的
视力问题,一种被称为持续性胎儿血管系统(PFV)疾病的疾病。确切的患病率
PFV是未知的;然而,美国一项关于儿童失明和视力丧失的研究表明,
PFV占所有儿童失明病例的5%。我们以前对PFV的研究的一个主要发现是
星形胶质细胞异常迁移到玻璃体中并包裹玻璃体动脉,这表明
以及星形胶质细胞联合与血管潴留之间的关系。目前还不知道星形胶质细胞
参与玻璃体动脉的形成或消退。我们的数据显示,
星形胶质细胞中的溶酶体功能与星形胶质细胞迁移和玻璃体鞘化的增加有关
动脉除了我们已经研究过的,几种PFV小鼠模型似乎有星形胶质细胞
与玻璃体动脉相连重要的是,我们还发现星形胶质细胞异常地
在PFV患者的临床标本中包裹玻璃体动脉。PFV涉及组件的持久性
通常短暂的胎儿眼内血管系统,并可以在完整性方面变化很大,
严重性。虽然玻璃体中血管内皮生长因子(VEGF)的增加肯定是一个重要的因素,
在重度PFV的病因学中,它可能不是轻度或中度PFV的情况。我们在本提案中的重点
是开发一种治疗轻度/中度疾病的方法。PFV是一种复杂的异质性疾病,
治疗可能对所有患者有效。适当的治疗可能取决于疾病的严重程度。
对于纤维化茎的严重疾病,我们在这里开发的药物可能是有效的,如果在
玻璃体切除术,类似于在糖尿病牵引脱离的玻璃体切除术前给予抗VEGFA注射
使手术技术更简单,减少术中和术后并发症。这里我们
将测试假设,“恢复正常的星形胶质细胞功能是一种有效的治疗策略,
PFV病”。这一目标将通过实现以下具体目标来实现:具体目标1:
为了证明过表达β-A1-晶状体蛋白是否可以恢复星形胶质细胞的功能,从而挽救星形胶质细胞的功能,
PFV样表型;具体目的2:检测是否抑制吉非替尼并激活自噬溶酶体
重建触发玻璃体血管的正常消退,具体目标3:确定因素
由能抑制胎儿正常发育重塑(退化)的CD 1A 1 KD星形胶质细胞释放
脉管系统这项拟议中的研究意义重大,因为我们现在有合适的动物模型进行测试
新的治疗方法来治疗PFV的基础上,我们的研究。很明显,大多数患有PFV的儿童
视觉效果不佳。因此,即使只有少数患者显著受益于
治疗,它仍然是一个重要的治疗进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEBASISH SINHA其他文献
DEBASISH SINHA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEBASISH SINHA', 18)}}的其他基金
Genetic analysis of a spontaneous mutation in a rat with a novel hind limb defect
新型后肢缺陷大鼠自发突变的遗传分析
- 批准号:
7806524 - 财政年份:2009
- 资助金额:
$ 39.75万 - 项目类别:
A CRYSTALLIN MUTATION WITH ABNORMAL ASTROCYTES AND RETINAL VESSELS
晶状体蛋白突变导致星形胶质细胞和视网膜血管异常
- 批准号:
7876821 - 财政年份:2009
- 资助金额:
$ 39.75万 - 项目类别:
Genetic analysis of a spontaneous mutation in a rat with a novel hind limb defect
新型后肢缺陷大鼠自发突变的遗传分析
- 批准号:
7658476 - 财政年份:2009
- 资助金额:
$ 39.75万 - 项目类别:
A CRYSTALLIN MUTATION WITH ABNORMAL ASTROCYTES AND RETINAL VESSELS
晶状体蛋白突变导致星形胶质细胞和视网膜血管异常
- 批准号:
7350844 - 财政年份:2009
- 资助金额:
$ 39.75万 - 项目类别:
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature
一种新的 bA3/A1-晶状体蛋白基因突变导致胎儿血管系统持续存在
- 批准号:
7674592 - 财政年份:2008
- 资助金额:
$ 39.75万 - 项目类别:
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature
一种新的 bA3/A1-晶状体蛋白基因突变导致胎儿血管系统持续存在
- 批准号:
8371561 - 财政年份:2008
- 资助金额:
$ 39.75万 - 项目类别:
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature
一种新的 bA3/A1-晶状体蛋白基因突变导致胎儿血管系统持续存在
- 批准号:
8513996 - 财政年份:2008
- 资助金额:
$ 39.75万 - 项目类别:
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature
一种新的 bA3/A1-晶状体蛋白基因突变导致胎儿血管系统持续存在
- 批准号:
8883541 - 财政年份:2008
- 资助金额:
$ 39.75万 - 项目类别:
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature
一种新的 bA3/A1-晶状体蛋白基因突变导致胎儿血管系统持续存在
- 批准号:
8715813 - 财政年份:2008
- 资助金额:
$ 39.75万 - 项目类别:
A novel bA3/A1-crystallin gene mutation results in persistent fetal vasculature
一种新的 bA3/A1-晶状体蛋白基因突变导致胎儿血管系统持续存在
- 批准号:
7888266 - 财政年份:2008
- 资助金额:
$ 39.75万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 39.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists